Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746989 · ClinicalTrials.gov registry record
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
A clinical trial of Gout, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 294,878
- Enrollment target
- 1
- Study location
NCT04746989: Completed study of Gout, sponsored by Brigham and Women's Hospital.
NCT04746989 is a study of Gout that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 294,878 participants, above the 215-participant average among 34 other Gout trials with a reported enrollment target (137053% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04746989, a study of Gout, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 294,878 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Primary Outcome
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Conditions Studied
Interventions
- DRUG Allopurinol
- DRUG Probenecid
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294,878 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2023-12-31 |
What the finished NCT04746989 record still lists
NCT04746989 is an observational study that tracks outcomes without assigning an intervention. Its 294,878 participants enrollment target places it among the larger protocols in the corpus, above the 215-participant average among 34 other Gout trials with a reported enrollment target (137053% higher).
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 2 interventions - of which Allopurinol is the first listed.
NCT04746989 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04746989 about?
NCT04746989 is a clinical study titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol". This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
What is the current status of trial NCT04746989?
This trial is currently completed. The enrollment target is 294,878 participants. The study started on 2021-02-01. Estimated completion is 2023-12-31.
What conditions does trial NCT04746989 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT04746989?
The interventions under investigation include: Allopurinol (DRUG), Probenecid (DRUG).
Who is sponsoring clinical trial NCT04746989?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04746989 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04746989's enrollment target sits among peer trials
294,878 1st of 34 higher than 34 of 34 other Gout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
RECRUITING · Phase 2
-
Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
RECRUITING · Phase 4
-
A Study of Dotinurad Versus Allopurinol in Participants With Gout
RECRUITING · Phase 3
-
Dose Response of Exercise for Arthritis Management
RECRUITING · NA
-
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI